Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-label, Controlled, Multi-center Extension Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)
Conditions
Interventions
MenABCWY+OMV vaccine
Locations
7
Chile
GSK Investigational Site
Santiago, Chile
GSK Investigational Site
Bogotá, Colombia
GSK Investigational Site
Bogotá, Colombia
GSK Investigational Site
Panama City, Panama
GSK Investigational Site
Panama City, Panama
GSK Investigational Site
Panama City, Panama
Start Date
June 30, 2015
Primary Completion Date
November 14, 2015
Completion Date
December 10, 2015
Last Updated
July 9, 2020
NCT04886154
NCT01725217
NCT03694405
NCT01939158
NCT04358731
NCT01266993
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions